WolverHeme Happy Hour23 Nov 2022

Episode 8: Pulling the Goalie on FLT3 Inhibitor Use in AML - A Discussion with Dr. Dale Bixby

In this enlightening episode, Anthony and Bernie chat about FLT3+ AML with Dr. Dale Bixby, Clinical Professor and expert in leukemia at the University of Michigan. We use two clinical cases to take a deep dive into the biology and prognostic implications of FLT3+ AML, pitfalls and controversies of variant allele frequency and allelic ratio testing, and the data that informs the use of FLT3 inhibitors in AML. Watch out for some possibly heretical views!

REFERENCES

Schlenk and Dohner (Impact of AML prognostic markers)l: https://pubmed.ncbi.nlm.nih.gov/19468271/

RATIFY Trial: https://www.nejm.org/doi/full/10.1056/nejmoa1614359

QUANTUM-FIRST: https://library.ehaweb.org/eha/2022/eha2022-congress/356965/harry.erba.quizartinib.prolonged.survival.vs.placebo.plus.intensive.induction.html?f=menu%3D6%2Abrowseby%3D8%2Asortby%3D2%2Amedia%3D3%2Ace_id%3D2233%2Amarker%3D1749%2Afeatured%3D17676

ODAC Review of Quantum-R (quizartinib): https://www.fda.gov/media/124896/download

ELN 2022: https://pubmed.ncbi.nlm.nih.gov/35797463/

WHO Myeloid 2022: https://pubmed.ncbi.nlm.nih.gov/35732831/

Sorafenib Maintenance (RCT China): https://pubmed.ncbi.nlm.nih.gov/32791048/

SorMAIN: https://pubmed.ncbi.nlm.nih.gov/32673171/

RADIUS (midostaurin maintenance): https://pubmed.ncbi.nlm.nih.gov/33288862/

LACEWING Trial: https://pubmed.ncbi.nlm.nih.gov/35917453/

HMA/Ven pooled FLT3: https://pubmed.ncbi.nlm.nih.gov/35063965/

Ven/Aza/Gilteritinib ASH 2022: https://ash.confex.com/ash/2022/webprogram/Paper157210.html

UK NCRI AML 17 Flt3 analysis: https://pubmed.ncbi.nlm.nih.gov/27268085/

Det här avsnittet är hämtat från ett öppet RSS-flöde och publiceras inte av Podme. Det kan innehålla reklam.

Avsnitt(50)

VAR Review with Dr. Bixby: Reversing the Call on MPAL

In this episode, Anthony and Bernie are joined by the great Dr. Bixby to discuss the difficulties in the diagnosis and treatment of acute leukemias of mixed or ambiguous lineage (ALAL/MPAL). We discus...

1 Juli 1h 6min

Bispecifics ate CAR-T's lunch: a multiple myeloma debate

In this episode, Bernie and Anthony are joined by Myeloma Man Manni Mohyuddin, MD to discuss the debate surrounding the treatment of first relapse in multiple myeloma. Should we be using CAR-T? Bispec...

11 Juni 56min

Episode 47: Cult-Like Thinking in BMT

“However much we flatter ourselves about our individual rationality, a good story, no matter how analytically deficient, lingers in the mind, resonates emotionally, and persuades more than the most di...

4 Juni 45min

Spring Cleaning the Evidence from ASH 2025 with Common Sense Oncology

In this special video episode, Bernie and Anthony moderate a Common Sense Oncology discussion of key trials from ASH 2025! We are joined by special guest experts from across the globe to critically ap...

13 Apr 1h 1min

HLH: From Chaos to Clarity... and Back to Chaos!

In this episode, Anthony and Bernie are joined by a panel of experts to discuss (and debate) everyone's favorite (or most feared) hematology topic - hemophagocytic lymphohistiocytosis (HLH)! Joining u...

20 Mars 1h 4min

An Exercise in Uncertainty with Jonathan Gluck

Anthony and Bernie are joined by special guest Jonathan Gluck, award-winning journalist and author of "An Exercise in Uncertainty: A Memoir of Illness and Hope" for a powerful conversation about livin...

10 Feb 46min

ASH Leukemia Review: the more we learn, the less we know!

In this episode, Anthony and Bernie are joined by special guest, Dr. Justin Kaner from Weill Cornell Medicine, to discuss some of the most interesting ASH abstracts in leukemia in 2025! What abstracts...

17 Dec 20251h 23min

RIP 7+3 (1973-2025)? Why PARADIGM Doesn't Deliver the Eulogy

Anthony and Bernie discuss the PARADIGM study that was presented at the plenary session of ASH 2025 and whether results should change our practice. https://meetings-api.hematology.org/api/abstract/vmp...

9 Dec 202541min